CORT

Corcept Therapeutics Incorporated

NasdaqCMUSDEQUITY DELAYED

122.25

▲ 1.20 (0.99%)

MARKET · —

Price

Open

122.50

Prev close

121.05

Day high

123.44

Day low

120.56

Volume

639.35K

Market cap

—

P/E (TTM)

—

52W range

28.66 – 123.44

Trailing performance

Price return · vs SPY

Returnvs SPY

+6.80% +8.2%

+26.47% +22.7%

+104.81% +101.7%

+251.09% +240.0%

YTD

+251.29% +239.0%

+73.65% +53.7%

+300.03% +225.9%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

116.08

+5.31% from price

SMA 20

111.20

+9.94% from price

SMA 50

97.31

+25.63% from price

SMA 100

75.67

+61.56% from price

SMA 200

64.79

+88.69% from price

EMA 12

115.43

+5.91% from price

EMA 26

108.32

+12.86% from price

EMA 50

97.91

+24.86% from price

RSI (14)

71.1

Overbought

MACD (12,26,9)

7.11

Hist 0.28

ATR (14)

3.58

2.92% of price

Realised vol 30D

83.1%

Annualised

Bollinger upper

128.45

20, 2σ

Bollinger lower

93.95

20, 2σ

50 / 200 cross

Golden

97.31 vs 64.79

Trend bias

Above 200

+88.69%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.80

More volatile than market

Correlation to SPY

0.28

Largely independent

Realised vol 30D

83.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-64.4%

Peak to trough

Max drawdown 5Y

-71.9%

Peak to trough

ATR 14

3.58

2.92% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 122.25

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

CORT · links out to the publisher

1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm StockStory · 23h ago Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT) StockStory · 2d ago Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating MT Newswires · 4d ago 1 Surging Stock to Own for Decades and 2 We Brush Off StockStory · 6d ago Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales Simply Wall St. · 15d ago Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation Barchart · 17d ago What IJR's Own History Says About Its Price Today Trefis · 18d ago John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics Inc at a -1.1% Portfolio Impact GuruFocus.com · 19d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.